 |
 |
On Mon 13 Sep, janet paterson wrote: > Pharmacodynamic and pharmacokinetic features of cabergoline. > Rationale for use in Parkinson's disease. > > The appearance of late motor complications is the major drawback of long > term levodopa therapy in patients with Parkinson's disease. > > I have been deriving a lot of amusement from the renewed interest in Cabergoline. It is a drug caught in a time-warp: If you go back through the records, you will begin to see a pattern. First there is the manufacturer's formal announcement of his latest wonder-drug. Then there are a number of studies published which tend to re-inforce the claims for the drug. Then there is an uneasy silence, maybe a year or two, where you begin to wonder if things are OK, followed by a slow or fast rise in the number of side-effects or similar results. In the case of Cabergoline, we know that the drug never went any further. , so that we have the initial reports, and that is it. So no wonder it looks so good - they all do at this stage. My advice to those reading the reports on Cabergoline : Try not to get carried away on a cloud of euphoria. It may produce the goods, and then again, it may not. Regards -- Brian Collins <[log in to unmask]>